Form 4 Filing for BRAINSTORM CELL THERAPEUTICS INC.

This filing details a Form 4 submission for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) concerning transactions by Chaim Lebovits, President & CEO. On February 26, 2026, Mr. Lebovits acquired 1,800,000 shares of Common Stock through restricted stock units (RSUs) awarded under a plan. These RSUs vest in two tranches: 50% on the grant date and the remaining 50% six months later, contingent upon continued employment. The acquisition was reported with a transaction price of $0.00 per share. Following this transaction, Mr. Lebovits holds 2,000,960 shares. The filing indicates that the reporting owner is an officer of the company and that the transaction was not subject to Section 16 reporting requirements.